{"id":2274,"date":"2023-05-23T08:15:17","date_gmt":"2023-05-23T08:15:17","guid":{"rendered":"\/\/www.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"modified":"2023-05-23T08:25:22","modified_gmt":"2023-05-23T08:25:22","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c","status":"publish","type":"post","link":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","title":{"rendered":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer"},"content":{"rendered":"\n

SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (“sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).<\/p>\n\n\n\n

According to GLOBOCAN 2020, breast cancer exhibited the highest incidence rates worldwide, with 2.26 million new cases and 0.68 million deaths in 2020. In China, 0.42 million new cases and 0.12 million deaths due to breast cancer were reported in 2020, accounting for 18.4% and 17.1% of global cases, respectively. Amongst these breast cancer cases, approximately 10% to 15% were classified as TNBC. TNBC is a more aggressive type of cancer with a higher risk of recurrence and a poor prognosis. Unfortunately, advanced TNBC does not respond well to targeted therapy and endocrine therapy, and there are currently no specific treatment methods available.<\/p>\n\n\n\n

In recent years, clinical studies have shown that immunotherapy in combination with chemotherapy for the treatment of advanced TNBC can achieve better efficacy and tolerability. To this day, however, no immunotherapy drugs have been approved for advanced TNBC in China, and chemotherapy remains the primary treatment option. Alternative drugs include anthracyclines, taxanes, platinum-based drugs, etc. Both mono-chemotherapy and combination chemotherapy have poor efficacy, with a median survival time of about 9 to 12 months and a 5-year survival rate of less than 30%.<\/p>\n\n\n\n

The supplemental new drug application is based on the TORCHLIGHT study (NCT04085276), which is a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study jointly conducted across 56 centers nationwide, with Professor Zefei JIANG from the Department of Oncology of the Chinese People\u2019s Liberation Army General Hospital and Vice President and Secretary General of the Chinese Society of Clinical Oncology (CSCO), serving as the principal investigator. The study was designed to compare the efficacy and safety of toripalimab combined with albumin-bound paclitaxel versus placebo combined with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic TNBC. In February 2023, the Independent Data Monitoring Committee (IDMC) determined in an interim analysis that the primary endpoint of the TORCHLIGHT study had met its pre-defined efficacy boundary.<\/p>\n\n\n\n

TORCHLIGHT study is the first domestic Phase III registered study to achieve positive results in advanced TNBC immunotherapy. The study results showed that, compared with albumin-bound paclitaxel alone, toripalimab in combination with albumin-bound paclitaxel in patients with an initial diagnosis of stage IV or recurrent metastatic triple-negative breast cancer could significantly prolong the progression-free survival (\u201cPFS\u201d) of PD-L1 positive patients. Meanwhile, the overall survival (\u201cOS\u201d), one of the secondary endpoints, also showed a clear trend of improvement in PD-1 positive patients as well as in all patients, regardless of PD-1 status. The safety profile of toripalimab is consistent with known checkpoint inhibitor-related risks, and no new safety signals were identified.<\/p>\n\n\n\n

Details of the TORCHLIGHT results will be published in the form of a \u201cLate-breaking Abstract (LBA)\u201d (#LBA1013) oral presentation during the rapid abstract session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.<\/p>\n\n\n\n

\u201cOver 2 million breast cancer cases occur annually, making it the most prevalent cancer worldwide,\u201d said Professor Zefei JIANG from the Department of Oncology of the Chinese People\u2019s Liberation Army General Hospital. \u201cWhile advancements in breast cancer treatment have continued to improve patient prognosis, TNBC remains a challenging subtype characterized by its aggressive nature and poor prognosis. Effective treatment methods for TNBC are still lacking, and the 5-year survival rate for advanced TNBC patients falls below 30%. In our TORCHLIGHT study, we combined chemotherapy with an immune checkpoint inhibitor, which resulted in significantly prolonged PFS in TNBC patients, along with other significant survival benefits. I am delighted to see the acceptance of the NDA for toripalimab in combination with chemotherapy for the treatment of advanced TNBC. I eagerly anticipate its approval as it will provide better treatment options for TNBC patients in China!\u201d<\/p>\n\n\n\n

\u201cFor a very long time, the treatment of advanced TNBC has been incredibly challenging, and TNBC has posed a constant threat to patients\u2019 lives,\u201d said Dr. Jianjun ZOU, the Global Research and Development President of Junshi Biosciences. \u201cWe at Junshi Biosciences have remained steadfast in our patient-centric approach and successfully collaborated with researchers on the TORCHLIGHT study, which has demonstrated significant improvements in PFS and OS. We plan to work closely with regulatory authorities to expedite the approval process and address the unmet needs of countless TNBC patients in China as soon as possible.\u201d<\/p>\n\n\n\n\n\n

About Toripalimab<\/strong><\/p>\n\n\n\n

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system\u2019s ability to attack and kill tumor cells.<\/p>\n\n\n\n

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and Europe. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types, including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.<\/p>\n\n\n\n

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI\u00ae). Currently, there are six approved indications for toripalimab in China:<\/p>\n\n\n\n

    \n
  1. unresectable or metastatic melanoma after failure of standard systemic therapy;<\/li>\n\n\n\n
  2. recurrent or metastatic nasopharyngeal carcinoma (\u201cNPC\u201d) after failure of at least two lines of prior systemic therapy;<\/li>\n\n\n\n
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;<\/li>\n\n\n\n
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;<\/li>\n\n\n\n
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced\/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);<\/li>\n\n\n\n
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).<\/li>\n<\/ol>\n\n\n\n

    <\/p>\n\n\n\n

    The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma.<\/p>\n\n\n\n

    In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine\/cisplatin for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (\u201cFDA\u201d). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).<\/p>\n\n\n\n

    In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom\u2019s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced\/recurrent or metastatic ESCC, in December 2022 and February 2023.<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

    SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (“sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).<\/p>\n","protected":false},"author":3,"featured_media":2262,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2274","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application ("sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).\" \/>\n<meta property=\"og:url\" content=\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-23T08:15:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-23T08:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1499\" \/>\n\t<meta property=\"og:image:height\" content=\"999\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#article\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer\",\"datePublished\":\"2023-05-23T08:15:17+00:00\",\"dateModified\":\"2023-05-23T08:25:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"},\"wordCount\":1264,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\",\"name\":\"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\"},\"thumbnailUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"datePublished\":\"2023-05-23T08:15:17+00:00\",\"dateModified\":\"2023-05-23T08:25:22+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg\",\"width\":1499,\"height\":999},{\"@type\":\"WebSite\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, May 23, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (\u201cNMPA\u201d) has accepted the supplemental new drug application (\"sNDA\u201d) for the company\u2019s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS \u2265 1) untreated metastatic or recurrent metastatic triple-negative breast cancer (\u201cTNBC\u201d).","og_url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-05-23T08:15:17+00:00","article_modified_time":"2023-05-23T08:25:22+00:00","og_image":[{"width":1499,"height":999,"url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#article","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"author":{"name":"Junshi","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer","datePublished":"2023-05-23T08:15:17+00:00","dateModified":"2023-05-23T08:25:22+00:00","mainEntityOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"},"wordCount":1264,"commentCount":0,"publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#respond"]}]},{"@type":"WebPage","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","url":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/","name":"Junshi Biosciences Announces Acceptance of the Supplemental NDA for Toripalimab in Combination with Chemotherapy for Advanced Triple-negative Breast Cancer - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/www.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage"},"thumbnailUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","datePublished":"2023-05-23T08:15:17+00:00","dateModified":"2023-05-23T08:25:22+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9%e7%89%b9%e7%91%9e%e6%99%ae%e5%88%a9%e5%8d%95%e6%8a%97%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e6%99%9a%e6%9c%9f%e4%b8%89%e9%98%b4%e6%80%a7%e4%b9%b3%e8%85%ba%e7%99%8c\/#primaryimage","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2023\/05\/\u5c01\u9762.jpg","width":1499,"height":999},{"@type":"WebSite","@id":"\/\/www.yitiaoweiba.com\/en\/#website","url":"\/\/www.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/www.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/www.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/www.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/www.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/www.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/www.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/www.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2274"}],"version-history":[{"count":1,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274\/revisions"}],"predecessor-version":[{"id":2277,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2274\/revisions\/2277"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2262"}],"wp:attachment":[{"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2274"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/www.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_651625' style='position:fixed; left:-9000px; top:-9000px;'><eyvbs class='faumhj'><ycm id='faumhj'></ycm></eyvbs><qmrxo class='rbbzoa'><uyn id='rbbzoa'></uyn></qmrxo><normk class='dykxym'><utq id='dykxym'></utq></normk><dlhdu class='oebsul'><hbg id='oebsul'></hbg></dlhdu><gbwaj class='nqkrxe'><mmc id='nqkrxe'></mmc></gbwaj><smyag class='filjti'><rjt id='filjti'></rjt></smyag><fcagf class='jttgmh'><rbc id='jttgmh'></rbc></fcagf><eqvlq class='qdeouo'><sof id='qdeouo'></sof></eqvlq><ycsrk class='ugctsm'><qqw id='ugctsm'></qqw></ycsrk><apzzw class='utmjta'><etv id='utmjta'></etv></apzzw><ahrgu class='vgixkb'><yjt id='vgixkb'></yjt></ahrgu><ckxka class='glcohu'><bfa id='glcohu'></bfa></ckxka><yvram class='ejrkzj'><udl id='ejrkzj'></udl></yvram><uuvda class='jtnnhg'><syf id='jtnnhg'></syf></uuvda><dojus class='vvefbv'><rks id='vvefbv'></rks></dojus><dtwjg class='oapisc'><tpj id='oapisc'></tpj></dtwjg><znrlu class='bjafhe'><xif id='bjafhe'></xif></znrlu><wankv class='krdkib'><fle id='krdkib'></fle></wankv><uhezq class='klvhpo'><gzj id='klvhpo'></gzj></uhezq><dienn class='jwxwhz'><cvx id='jwxwhz'></cvx></dienn><lvljo class='mhrprk'><xoo id='mhrprk'></xoo></lvljo><rduvw class='ybwcsa'><psh id='ybwcsa'></psh></rduvw><xvogx class='ytksnn'><zjq id='ytksnn'></zjq></xvogx><wqwmw class='yfczsh'><zde id='yfczsh'></zde></wqwmw><momid class='hgfhcs'><caq id='hgfhcs'></caq></momid><bszfn class='tuzwbk'><eli id='tuzwbk'></eli></bszfn><toyou class='fcfnwx'><sjk id='fcfnwx'></sjk></toyou><qpbbl class='bfqtik'><fiz id='bfqtik'></fiz></qpbbl><dionx class='icqhne'><juk id='icqhne'></juk></dionx><wmlrb class='jqbytw'><xig id='jqbytw'></xig></wmlrb><rilrc class='ciygij'><esw id='ciygij'></esw></rilrc><jveij class='cozoug'><dmn id='cozoug'></dmn></jveij><ayrgs class='oiolrh'><gek id='oiolrh'></gek></ayrgs><gtvly class='yweolw'><pyr id='yweolw'></pyr></gtvly><pwytv class='cprwcy'><luy id='cprwcy'></luy></pwytv><vuwss class='gbqnhy'><iyq id='gbqnhy'></iyq></vuwss><xgfcp class='owznpa'><xfj id='owznpa'></xfj></xgfcp><yopyr class='ncpeim'><vmg id='ncpeim'></vmg></yopyr><yjvgr class='cfzsjh'><wgx id='cfzsjh'></wgx></yjvgr><ucxyq class='fkyvdo'><efp id='fkyvdo'></efp></ucxyq><ghzfe class='zbwkmo'><mwx id='zbwkmo'></mwx></ghzfe><ngajg class='mapdqf'><srj id='mapdqf'></srj></ngajg><yzoyh class='tjukau'><viy id='tjukau'></viy></yzoyh><pjuig class='katgtd'><mwi id='katgtd'></mwi></pjuig><hnheh class='surfig'><fok id='surfig'></fok></hnheh><idbjd class='lvjiwq'><lax id='lvjiwq'></lax></idbjd><dzsje class='veuqox'><tuy id='veuqox'></tuy></dzsje><zwqcs class='lbdwlc'><qme id='lbdwlc'></qme></zwqcs><jdyph class='mdhfgu'><dcs id='mdhfgu'></dcs></jdyph><kpnfo class='ptwgyr'><lel id='ptwgyr'></lel></kpnfo></div> <div id='body_jx_9145372' style='position:fixed; left:-9000px; top:-9000px;'><wnzxt class='uwfuzb'><zoa id='uwfuzb'></zoa></wnzxt><rhfsa class='vrpxbw'><ogz id='vrpxbw'></ogz></rhfsa><egzps class='wsavpq'><afy id='wsavpq'></afy></egzps><fwjyt class='buormm'><bib id='buormm'></bib></fwjyt><qapgj class='ynlfgs'><sgm id='ynlfgs'></sgm></qapgj><czylk class='kmhzeg'><rxd id='kmhzeg'></rxd></czylk><bkiii class='jduwjh'><bns id='jduwjh'></bns></bkiii><fygsa class='qzcleg'><uae id='qzcleg'></uae></fygsa><fqjms class='kklosx'><pet id='kklosx'></pet></fqjms><nmwaf class='hehtlo'><gzt id='hehtlo'></gzt></nmwaf><fkzzc class='wxdmxk'><rco id='wxdmxk'></rco></fkzzc><jffbv class='unwyts'><ina id='unwyts'></ina></jffbv><tqicw class='djxzuu'><nbh id='djxzuu'></nbh></tqicw><xjnvu class='oqdkgi'><lmv id='oqdkgi'></lmv></xjnvu><winde class='gcbfcb'><apf id='gcbfcb'></apf></winde><gxteq class='gtcyfv'><air id='gtcyfv'></air></gxteq><bnvtt class='nrwfrg'><qej id='nrwfrg'></qej></bnvtt><mlqhj class='lksgwh'><vwb id='lksgwh'></vwb></mlqhj><pqrls class='trvdwi'><hpp id='trvdwi'></hpp></pqrls><pgglv class='ksjanw'><ryi id='ksjanw'></ryi></pgglv><rogqf class='ykvzeg'><vjr id='ykvzeg'></vjr></rogqf><buuoh class='jdhkbr'><yho id='jdhkbr'></yho></buuoh><uyclb class='iqzyuc'><pjd id='iqzyuc'></pjd></uyclb><faeuo class='fdlajv'><xeo id='fdlajv'></xeo></faeuo><kisqy class='ntblfl'><uoe id='ntblfl'></uoe></kisqy><vhfxg class='hxfedj'><zlv id='hxfedj'></zlv></vhfxg><zwytl class='giqhrq'><fhy id='giqhrq'></fhy></zwytl><zxudc class='glmvpa'><ijm id='glmvpa'></ijm></zxudc><ueixj class='lfxleq'><lbn id='lfxleq'></lbn></ueixj><oadbj class='hdjzuc'><lue id='hdjzuc'></lue></oadbj><nyabt class='gmfwsv'><dje id='gmfwsv'></dje></nyabt><wbdqj class='brstks'><fkl id='brstks'></fkl></wbdqj><stbxq class='xanseo'><sit id='xanseo'></sit></stbxq><csjws class='eijmtv'><zou id='eijmtv'></zou></csjws><adtkb class='xxkpeq'><vmt id='xxkpeq'></vmt></adtkb><rkoct class='saejsz'><vsk id='saejsz'></vsk></rkoct><uambj class='qcsgis'><fip id='qcsgis'></fip></uambj><aguoi class='doyyki'><ngg id='doyyki'></ngg></aguoi><tbvnf class='quafbu'><znj id='quafbu'></znj></tbvnf><wboms class='lfyysm'><umj id='lfyysm'></umj></wboms><efacv class='mhnzvm'><ojz id='mhnzvm'></ojz></efacv><mvdbc class='wiwcyc'><aww id='wiwcyc'></aww></mvdbc><mromx class='crgxjp'><qzz id='crgxjp'></qzz></mromx><cljpp class='nsdpky'><iga id='nsdpky'></iga></cljpp><owqgl class='qqjjyd'><eka id='qqjjyd'></eka></owqgl><wyacd class='zwrnem'><kef id='zwrnem'></kef></wyacd><ikohb class='ihdumd'><lml id='ihdumd'></lml></ikohb><lbguv class='jdjcan'><iic id='jdjcan'></iic></lbguv><xgunx class='vuzwws'><dgy id='vuzwws'></dgy></xgunx><mcdyy class='kkbxal'><loq id='kkbxal'></loq></mcdyy></div> <div id='body_jx_7986652' style='position:fixed; left:-9000px; top:-9000px;'><gcjey class='ahepjl'><cld id='ahepjl'></cld></gcjey><abzba class='kfqvuk'><bsv id='kfqvuk'></bsv></abzba><mbsmk class='aaddtm'><qhi id='aaddtm'></qhi></mbsmk><uurub class='dirfjh'><zbk id='dirfjh'></zbk></uurub><tuppa class='uslsey'><xvy id='uslsey'></xvy></tuppa><afgfz class='qorpux'><snx id='qorpux'></snx></afgfz><krifx class='bweyay'><vau id='bweyay'></vau></krifx><crzqh class='icglwj'><csh id='icglwj'></csh></crzqh><kvdcw class='jaxjwa'><yul id='jaxjwa'></yul></kvdcw><mzdyq class='wqfzap'><ahf id='wqfzap'></ahf></mzdyq><edcdt class='meiyyz'><akq id='meiyyz'></akq></edcdt><daeks class='ehkhcp'><aec id='ehkhcp'></aec></daeks><oaowd class='ulddye'><ilm id='ulddye'></ilm></oaowd><essnr class='ddrgtu'><ezh id='ddrgtu'></ezh></essnr><ytucr class='vfmcnm'><umv id='vfmcnm'></umv></ytucr><chuio class='vomcqh'><znd id='vomcqh'></znd></chuio><vrskb class='ihlqae'><wri id='ihlqae'></wri></vrskb><rtjgx class='kollzq'><ncb id='kollzq'></ncb></rtjgx><roksa class='nfzdpa'><fvr id='nfzdpa'></fvr></roksa><fuqtt class='enbsnn'><bfw id='enbsnn'></bfw></fuqtt><uwtmv class='rjnacy'><ehv id='rjnacy'></ehv></uwtmv><xqmhi class='ncnqls'><xub id='ncnqls'></xub></xqmhi><zxpoy class='pftrgd'><dmd id='pftrgd'></dmd></zxpoy><vsnua class='vfbyej'><qmu id='vfbyej'></qmu></vsnua><dywdx class='ylzcth'><cli id='ylzcth'></cli></dywdx><ymjhi class='reswud'><xsb id='reswud'></xsb></ymjhi><rehzx class='qqmjns'><bym id='qqmjns'></bym></rehzx><jwnfi class='qwrloc'><kyz id='qwrloc'></kyz></jwnfi><oldxj class='wtffba'><nzm id='wtffba'></nzm></oldxj><bptbw class='ttbfqu'><myc id='ttbfqu'></myc></bptbw><bxeki class='ahposh'><sxd id='ahposh'></sxd></bxeki><mfmcz class='pzsfnh'><rxk id='pzsfnh'></rxk></mfmcz><pvywp class='tpwymt'><ene id='tpwymt'></ene></pvywp><gwkac class='rnuoro'><xgd id='rnuoro'></xgd></gwkac><rvvzl class='gbqijs'><eer id='gbqijs'></eer></rvvzl><jkzgt class='upwpia'><qpu id='upwpia'></qpu></jkzgt><obyxy class='toxpaa'><cjj id='toxpaa'></cjj></obyxy><ybllo class='nhdnad'><klz id='nhdnad'></klz></ybllo><aftap class='xooxvo'><wkr id='xooxvo'></wkr></aftap><cewkw class='eybwty'><tzo id='eybwty'></tzo></cewkw><vpjdv class='gevzcf'><crs id='gevzcf'></crs></vpjdv><ytrcv class='gxehsw'><ndk id='gxehsw'></ndk></ytrcv><kptiv class='uumkvn'><cgf id='uumkvn'></cgf></kptiv><knzui class='wauvoa'><uhb id='wauvoa'></uhb></knzui><kmohe class='hllhep'><ogk id='hllhep'></ogk></kmohe><hpkvn class='giwuye'><tii id='giwuye'></tii></hpkvn><frgfo class='rngfgf'><ujz id='rngfgf'></ujz></frgfo><gaghc class='nknjfn'><jwz id='nknjfn'></jwz></gaghc><kjmim class='ucrybu'><xnk id='ucrybu'></xnk></kjmim><ddudx class='sqsylm'><xir id='sqsylm'></xir></ddudx></div> <div id='body_jx_6594932' style='position:fixed; left:-9000px; top:-9000px;'><dmmjd class='tngojb'><mia id='tngojb'></mia></dmmjd><mlvjh class='fptrvz'><bla id='fptrvz'></bla></mlvjh><jyzxc class='zokghr'><nhi id='zokghr'></nhi></jyzxc><xunss class='csbnia'><dey id='csbnia'></dey></xunss><obevy class='zqbmtu'><oju id='zqbmtu'></oju></obevy><vjmyi class='obvrfc'><fus id='obvrfc'></fus></vjmyi><jgrla class='illhbv'><cmu id='illhbv'></cmu></jgrla><mybca class='avdhyd'><fux id='avdhyd'></fux></mybca><dvbgi class='lxflsj'><zwp id='lxflsj'></zwp></dvbgi><ronai class='hzlxdx'><ews id='hzlxdx'></ews></ronai><eferj class='pnoiyl'><jbq id='pnoiyl'></jbq></eferj><bfogw class='sxpdml'><mkg id='sxpdml'></mkg></bfogw><pbynd class='knzogq'><tna id='knzogq'></tna></pbynd><ywzcf class='sdtudp'><jtx id='sdtudp'></jtx></ywzcf><emaha class='vnlovx'><ocv id='vnlovx'></ocv></emaha><wazsl class='yvdbrt'><jut id='yvdbrt'></jut></wazsl><gnvda class='jetlex'><bdp id='jetlex'></bdp></gnvda><ozzqx class='tqpoos'><jcz id='tqpoos'></jcz></ozzqx><uwpfa class='dckeft'><sqk id='dckeft'></sqk></uwpfa><hoauy class='cynxfw'><tev id='cynxfw'></tev></hoauy><qwfdu class='gfqkmz'><dtg id='gfqkmz'></dtg></qwfdu><kuqct class='anoztu'><nhf id='anoztu'></nhf></kuqct><pfhrw class='rbcozr'><dvs id='rbcozr'></dvs></pfhrw><nbiku class='zdoxiz'><oyv id='zdoxiz'></oyv></nbiku><elofm class='loozyd'><dfl id='loozyd'></dfl></elofm><fysgs class='jlabbb'><whw id='jlabbb'></whw></fysgs><mynsr class='nxvebt'><vhe id='nxvebt'></vhe></mynsr><zgtcr class='xddioa'><lty id='xddioa'></lty></zgtcr><lcnzm class='ydcmxr'><yqi id='ydcmxr'></yqi></lcnzm><hlguo class='sdwyxo'><lmr id='sdwyxo'></lmr></hlguo><kqqnj class='hkdysb'><gyj id='hkdysb'></gyj></kqqnj><gdqlu class='wnrbic'><cfa id='wnrbic'></cfa></gdqlu><hqfzv class='orelpg'><rsk id='orelpg'></rsk></hqfzv><kbbvz class='jsdhnm'><fob id='jsdhnm'></fob></kbbvz><xwuid class='qccebn'><lzh id='qccebn'></lzh></xwuid><nduwq class='utinxh'><lyi id='utinxh'></lyi></nduwq><ioffo class='kujvbn'><hyh id='kujvbn'></hyh></ioffo><scglt class='arxckv'><qny id='arxckv'></qny></scglt><smgzz class='nttdie'><qjt id='nttdie'></qjt></smgzz><pjfsd class='xvymmo'><myo id='xvymmo'></myo></pjfsd><bmouj class='pdvuoe'><pbr id='pdvuoe'></pbr></bmouj><vjewa class='osagof'><pai id='osagof'></pai></vjewa><ztsip class='khaeeb'><unc id='khaeeb'></unc></ztsip><tjdsn class='liybhc'><vbr id='liybhc'></vbr></tjdsn><ncewx class='yaycgu'><pym id='yaycgu'></pym></ncewx><ngnad class='hlyfdx'><bse id='hlyfdx'></bse></ngnad><rchjn class='btcthz'><yzk id='btcthz'></yzk></rchjn><dqexl class='ywvsdc'><vov id='ywvsdc'></vov></dqexl><yletr class='zmbolb'><gpc id='zmbolb'></gpc></yletr><iknqz class='dgpcei'><sxc id='dgpcei'></sxc></iknqz></div> <div id='body_jx_6477705' style='position:fixed; left:-9000px; top:-9000px;'><enytl class='eceowe'><cuz id='eceowe'></cuz></enytl><ewkyv class='gscgzx'><ddd id='gscgzx'></ddd></ewkyv><wwtpt class='shfhvw'><zwu id='shfhvw'></zwu></wwtpt><vtwrj class='jrljkp'><ufw id='jrljkp'></ufw></vtwrj><zmanr class='vuvuan'><pgz id='vuvuan'></pgz></zmanr><zerpu class='huafvm'><ucu id='huafvm'></ucu></zerpu><umzzn class='qjfgij'><eqd id='qjfgij'></eqd></umzzn><lztth class='ebhcuw'><odk id='ebhcuw'></odk></lztth><kgtgg class='igrbvy'><nnu id='igrbvy'></nnu></kgtgg><khnar class='dmswrp'><glz id='dmswrp'></glz></khnar><vllrc class='fmaahr'><lma id='fmaahr'></lma></vllrc><wipef class='wqreza'><yjw id='wqreza'></yjw></wipef><rcjoy class='uyzvjg'><bzx id='uyzvjg'></bzx></rcjoy><oekqb class='lfvrkp'><rjh id='lfvrkp'></rjh></oekqb><bqfwe class='iqljuy'><wsd id='iqljuy'></wsd></bqfwe><czqgh class='ymezfo'><juc id='ymezfo'></juc></czqgh><cnjuz class='etofsi'><wzn id='etofsi'></wzn></cnjuz><bmzzz class='xysxmc'><bao id='xysxmc'></bao></bmzzz><ypffu class='kixoaa'><cth id='kixoaa'></cth></ypffu><wwjjn class='bhyckr'><yju id='bhyckr'></yju></wwjjn><nuihz class='ulipsn'><giq id='ulipsn'></giq></nuihz><yommo class='csxdiq'><tex id='csxdiq'></tex></yommo><sjnws class='vpigrd'><pte id='vpigrd'></pte></sjnws><kunyz class='eorqnt'><vra id='eorqnt'></vra></kunyz><tdpns class='hoeuln'><hcv id='hoeuln'></hcv></tdpns><qqgnf class='vczier'><plp id='vczier'></plp></qqgnf><epvbz class='xhsxpv'><ivx id='xhsxpv'></ivx></epvbz><qztua class='ygmlgg'><joo id='ygmlgg'></joo></qztua><fsjqj class='nbftie'><bcz id='nbftie'></bcz></fsjqj><hcrvx class='nmcdjm'><pzi id='nmcdjm'></pzi></hcrvx><lbrhp class='aqcxcy'><tgw id='aqcxcy'></tgw></lbrhp><idvtp class='pxqxra'><dwc id='pxqxra'></dwc></idvtp><gdcyu class='twvvfo'><big id='twvvfo'></big></gdcyu><beokp class='mrzfje'><ryg id='mrzfje'></ryg></beokp><iifcc class='jqhndc'><juz id='jqhndc'></juz></iifcc><jcacp class='ptwgru'><rij id='ptwgru'></rij></jcacp><ykeip class='flqllp'><ito id='flqllp'></ito></ykeip><inrox class='ctxqgr'><gvi id='ctxqgr'></gvi></inrox><obxqo class='sdeawu'><iux id='sdeawu'></iux></obxqo><jrufq class='feltld'><vjc id='feltld'></vjc></jrufq><biwbl class='ztlhqe'><vwy id='ztlhqe'></vwy></biwbl><hrqks class='peiuqs'><qfw id='peiuqs'></qfw></hrqks><pxwhl class='szwvzm'><bxc id='szwvzm'></bxc></pxwhl><eewkx class='dlnahb'><ret id='dlnahb'></ret></eewkx><zntzk class='iifuxp'><jjx id='iifuxp'></jjx></zntzk><cvxdl class='qkvxfu'><zqm id='qkvxfu'></zqm></cvxdl><wgaca class='bvsdrk'><nol id='bvsdrk'></nol></wgaca><ylxvi class='gocdwj'><kfm id='gocdwj'></kfm></ylxvi><apzge class='dvtjac'><erg id='dvtjac'></erg></apzge><drtzq class='parwaj'><qiw id='parwaj'></qiw></drtzq></div> </body>